BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29295722)

  • 1. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
    Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
    Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
    Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
    Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
    Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
    Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of preliminary medication on oxaliplatin hypersensitivity].
    Sato J; Terui K; Hayakari M
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1125-9. PubMed ID: 19620801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
    Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
    Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity reactions associated with oxaliplatin and their clinical management.
    Toki MI; Saif MW; Syrigos KN
    Expert Opin Drug Saf; 2014 Nov; 13(11):1545-54. PubMed ID: 25307143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.
    Li M; Jiang C; Yang JW; Yu ZQ; Li W; Zhao L; Song QY; Zhang CL; Liu D
    Curr Med Sci; 2021 Aug; 41(4):827-831. PubMed ID: 34403109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment.
    Kim JJ; Kang J; Hong YS; Kim KP; Kim SY; Kim TW; Kim JE
    Med Oncol; 2018 Apr; 35(5):65. PubMed ID: 29623500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
    Tampellini M; Benedetto S; Rubatto E; Baratelli C; DI Scipio F; Pirro E; Brizzi MP; Sonetto C; DI Maio M; Berta GN; Scagliotti GV
    Anticancer Res; 2016 Oct; 36(10):5163-5170. PubMed ID: 27798876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
    Thomas RR; Quinn MG; Schuler B; Grem JL
    Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
    Wu HL
    J Oncol Pharm Pract; 2019 Sep; 25(6):1388-1395. PubMed ID: 30176784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premedication strategy for weekly paclitaxel.
    Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
    Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity to oxaliplatin: clinical features and risk factors.
    Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
    BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.
    Bano N; Najam R; Qazi F; Mateen A
    Asian Pac J Cancer Prev; 2016; 17(4):1637-41. PubMed ID: 27221832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.